An evaluation of asthma medication utilization for risk evaluation and mitigation strategies (REMS) in the United States: 2005–2011
- 25 June 2013
- journal article
- Published by Taylor & Francis Ltd in Journal of Asthma
- Vol. 50 (7), 776-782
- https://doi.org/10.3109/02770903.2013.803116
Abstract
Purpose: The purpose of this study was to assess drug utilization patterns of fluticasone propionate (FP)/salmeterol (SAL) combination (FSC) and SAL over the 7-year period of 2005–2011 in patients with asthma as part of the Risk Evaluation and Mitigation Strategies (REMS). Methods: A descriptive, retrospective observational study utilizing national pharmacy data and employer-based claims data to characterize drug utilization patterns. Results: For patients with asthma, the total number of FSC and SAL dispensings and users of FSC and SAL has declined between 2005 and 2011. During this period, FSC and SAL dispensing for asthma decreased 24% and 76%, respectively, with a more pronounced decline between 2010 and 2011 relative to other years. The total number of patients with asthma who were dispensed FSC has decreased by 10% among adults and by 40% in children and adolescents. While SAL-containing medications decreased, dispensing of FP monotherapy increased 39% during the same 7-year period. The number of patients dispensed FP for asthma has increased 47% in children 4–11 years of age, 72% in adolescents 12–17 years of age, and 6% in adults. SAL use without a controller was infrequent and decreasing, reported by 1.7% and 0.5% of patients with asthma in 2005 and 2011, respectively. Conclusions: In patients with asthma, use of FSC and SAL decreased between 2005 and 2011, while the use of FP increased. Use of SAL monotherapy was infrequent and declined during the study period. The data suggest that the substantial communication activities have encouraged appropriate prescribing of long-acting β2-adrenergic agonist (LABA).Keywords
This publication has 10 references indexed in Scilit:
- Characterization of Long-Acting Beta2-Adrenergic Agonists Utilization in Asthma PatientsJournal of Asthma, 2012
- Long-acting β-agonist prescribing in people with asthma in primary care: Table 1Thorax, 2012
- The FDA-mandated trial of safety of long-acting beta-agonists in asthma: finality or futility?Thorax, 2012
- Age and Risks of FDA-Approved Long-Acting β2-Adrenergic Receptor AgonistsPediatrics, 2011
- Prescription Patterns in Asthma Patients Initiating Salmeterol in UK General PracticeDrug Safety, 2011
- Appropriate use of inhaled corticosteroid and long-acting ß2-adrenergic agonist combination therapy among asthma patients in a US commercially insured populationCurrent Medical Research and Opinion, 2009
- Medication Compliance and Persistence: Terminology and DefinitionsValue in Health, 2008
- The Salmeterol Multicenter Asthma Research TrialSocial psychiatry. Sozialpsychiatrie. Psychiatrie sociale, 2006
- Adherence to asthma controller medication regimensRespiratory Medicine, 2005
- Serevent nationwide surveillance study: comparison of salmeterol with salbutamol in asthmatic patients who require regular bronchodilator treatment.BMJ, 1993